Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.39 |
| ▸ | CES1 | P23141 | 8/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | LIPA | P38571 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373902 | 0.86 | FAAH (0.53) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL28687905 | 0.84 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7638938 | 0.82 | TDP1 (0.41) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL6314290 | 0.82 | FAAH (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL5323967 | 0.81 | FAAH (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL23009369 | 0.81 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8562872 | 0.78 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL18844136 | 0.76 | FAAH (0.42) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7640644 | 0.75 | LIPA (0.39) | MEN1KMT2AHDAC6LIPA | |
| SCHEMBL4371316 | 0.75 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | IPMK, TALDO1, BCKDK | FAAH 3210/4885CES1 2112/4885CES2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.